the aid library

LIST OPTIONS

Filter

7628

Generic risk assessment model for insecticide-treated nets, 2nd ed.

World Health Organization (WHO) (2018) C_WHO

Long-lasting insecticidal nets (LNs) constitute a core vector control intervention against malaria. A number of new LN products are under development and will require assessment of risks to humans. This document provides an updated generic model that can be used for the risk assessment of exposure t... more

Download (196)

View PDF (248)

Community-Based Disaster Risk Reduction (CBDRR) Manual in Lao PDR

(2016) C1

The CBDRR Manual is a practical ‘how-to’ guide on community-based disaster risk reduction for government and non-government agencies in Lao PDR. It is a commonly agreed document to be referred to by agencies working on CBDRR in Lao PDR. It provides guidance and support for systematic implementat... more

Download (662)

View PDF (824)

Guidelines for the Clinical Management of HIV Infection in Myanmar, 5th ed.
recommended

The Republic of the Union of Myanmar, Ministry of Health, Department of Health, National AIDS Programme World Health Organization (WHO), Country Office for Myanmar (2017) C1

These guidelines aim to guide all health care providers in Myanmar, accommodating the situation of different settings in the context of progressive decentralization of HIV services. Notable changes from the previous edition include:
• diagnosis of HIV
• update on the initiation of ART<... more

Download (198)

View PDF (255)

CONSENSUS DOCUMENT FOR MANAGEMENT OF BUCCAL MUCOSA CANCER

Indian Council of Medical Research (ICMR) (2014) C1

Prepared as an outcome of ICMR Subcommittee on Buccal Mucosa Cancer | This consensus document on management of Buccal Mucosa cancers summarizes the modalities of treatment including the site-specific anti-cancer therapies, supportive and palliative care and molecular markers and research questions. ... more

Download (517)

View PDF (1020)

Management of physical health conditions in adults with severe mental disorders
recommended

World Health Organization WHO (2018) C_WHO

The global burden of disease due to mental disorders continues to rise, especially in low- and middle-income countries (LMIC). In addition to causing a large proportion of morbidity, mental disorders – especially severe mental disorders (SMD) – are linked with poorer health outcomes and increase... more

External Link

Defining, treating and preventing hospital acquired pneumonia: European perspective

Torres, A.; Ewig S.; Lode, H.; et al. (2017) C2

Intensive Care Med (2009) 35:9–29DOI 10.1007/s00134-008-1336-9 Although thousands of papers have been devoted tohospital-acquired pneumonia (HAP), many controversiesremain, and management of HAP is probably often sub-optimal. Several reviews or guidelines have been pub-lished rec... more

Download (101)

View PDF (149)

The impact of the COVID-19 pandemic on Syrians: An Analysis by Syrian civil society

Half of Syria (2020) C2

A comprehensive briefing by Half of Syria April 2020 A comprehensive briefing on the critical challenges of the COVID-19 pandemic to Syrians, as reported by Syrian civil society organisations. These challenges have been collated following extensive interviews with the teams of member and partner... more

IASC Emergency Response Preparedness (ERP) Approach to the COVID-19 Pandemic - Preparedness, Early Action and Readiness Sub-Group

IASC (2020) C2

The interim Emergency Response Preparedness (ERP) guidance is designed to be a short technical step-by-step guide aimed at non-Humanitarian Response Plan (HRP) countries to support the development, or strengthening, of preparedness measures to ensure that country teams are operationally ready to imp... more

Download (119)

View PDF (143)

Child protection emergency preparedness and response guidance to the COVID-19

UNICEF East Asia and Pacific Region (2020) C_UNICEF

Infectious diseases, such as COVID-19, can have a significant impact on children’s and their caregivers’ wellbeing beyond the disease itself. In terms of child protection, there are three main potential secondary impacts: - Neglect and lack of parental care. - Mental health and Psychosocia... more

Download (130)

View PDF (150)

Preventing and managing COVID-19 across long-term care services

World Health Organization WHO (2020) C_WHO

Policy brief, 24 July 2020 The COVID-19 pandemic has affected older people disproportionately, especially those living in long-term care facilities. In many countries, evidence shows that more than 40% of COVID-19 related deaths have been linked to long-term care facilities, with figures being as h... more

Health Care Waste Management Policy for Ghana

Ministry of Health Ghana (2020) CC

Ghana's attempt to regulate health care waste management started in 2002 with the development of guidelines on health care waste manage-ment by the Environmental Protection Agency (EPA). In 2006, the Ministry of Health developed the health care waste policy and guidelines. This guidance document im... more

Download (114)

View PDF (147)

Prevention and control of noncommunicable diseases in Kyrgyzstan: the case for investment

World Health Organization WHO, Regional Office of Europe (2017) C_WHO

Noncommunicable diseases (‎NCDs)‎ such as cancer, cardiovascular diseases, diabetes and chronic respiratory diseases and their risk factors are an increasing public health and development challenge in Kyrgyzstan. This report provides evidence through three analyses that NCDs reduce economic outp... more

Download (211)

View PDF (248)

Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline
recommended

World Health Organization WHO (2022) C_WHO

This second edition of the Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline provides the most up to date technical guidance on mask use in community settings in the context of COVID-19. In this edition, new information includes updated mask re... more

Download (227)

View PDF (220)

Guidance to facilitate monitoring and evaluation for antimicrobial resistance national action plans

Quadripartite: Food and Agriculture Organization of the United Nations FAO; UN Environment Programme UNEP; World Health Organization WHO; World Organisation for Animal Health WAHO (2023) CC

Antimicrobial resistance (AMR) is a global human, animal, plant and environment health threat that needs to be addressed by every country. The impacts of AMR are wide-ranging in terms of human health, animal health, food security and safety, environmental effects on ecosystems and biodiversity, and ...socioeconomic development. Just like the climate crisis, AMR poses a significant threat to the delivery of the 2030 Agenda for Sustainable Development. The response to the AMR crisis has been spearheaded through the global action plan on antimicrobial resistance (GAP-AMR), developed by the World Health Organization (WHO) in 2015, in close collaboration with the Food and Agriculture Organization of the United Nations (FAO) and the World Organisation for Animal Health (WOAH), and formally endorsed by the three organizations’ governing bodies and by the Political Declaration of the high-level meeting of the United Nations General Assembly on AMR in 2016. In 2022, the three organizations officially became the Quadripartite by welcoming the United Nations Environment Programme (UNEP) into the alliance “to accelerate coordination strategy on human, animal and ecosystem health”. The aim of the GAP-AMR is to ensure the continuity of successful treatment with effective and safe medicines. Its strategic objectives include: • improving the awareness and understanding of AMR; • strengthening the knowledge and evidence base through surveillance and research; • reducing the incidence of infection through effective sanitation, hygiene and infection prevention measures; optimizing the use of antimicrobial medicines in human and animal health; and • developing the economic case for sustainable investment that takes account of the needs of all countries and increasing investment in new medicines, diagnostic tools, vaccines and other interventions. With the adoption of the GAP-AMR, countries agreed to develop national action plans (NAPs) aligned with the GAP-AMR to mainstream AMR interventions nationally. Individually, the Quadripartite took action to advance AMR interventions in their respective sectors. FAO adopted a resolution on AMR recognizing that it poses an increasingly serious threat to public health and sustainable food production, and developed an AMR action plan to support the resolution’s implementation. For its part, WOAH developed a strategy on AMR aligned with the GAP-AMR, acknowledging the importance of a One Health approach to AMR. Similarly, more recently, UNEP’s governing body, the United Nations Environment Assembly, recognized that AMR is a current and increasing threat and a challenge to global health, food security and the sustainable development of all countries, and welcomed the GAP-AMR and the NAPs developed in accordance with its five overarching strategic objectives more

Download (285)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

ICMR Guidlines for management of type 2 Diabetes

Indian Council of Medical Research (2018) CC2

In recent decades, India has witnessed a rapidly exploding epidemic of diabetes. Indeed, India today has the second largest number of people with diabetes in the world. The International Diabetes Federation (IDF) estimates that there are 72.9 million people with diabetes in India in 2017, which is... more

Risk factors for asthma among schoolchildren who participated in a casecontrol study in urban Uganda

Mpairwe, H.; Namutebi, M.; Nkurunungi, G. et al. eLife (2019) CC

Data on asthma aetiology in Africa are scarce. We investigated the risk factors for asthma among schoolchildren (5–17 years) in urban Uganda. We conducted a case-control study, among 555 cases and 1115 controls. Asthma was diagnosed by study clinicians. The main risk factors for asthma were tertia... more

Download (732)

View PDF (1526)

Guidelines on hepatitis B and C testing
recommended

World Health Organization (WHO) (2017) C_WHO

Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to recei... more

Download (270)

View PDF (396)

Rwanda: 2013-2014 ANNUAL REPORT - Tuberculosis, other respiratory communicable diseases and Leprosy control in Rwanda

Rwanda Biomedical Center - Institute of HIVAIDS, Disease prevention & Control (IHDPC), TB & Other Respiratory Communicable Diseases Division (2014) C2

This report has been developed, based on data provided by the TB & ORD surveillance system from across Rwanda. It provides a comprehensive picture of the occurrence and management of TB & ORD and Leprosy in Rwanda. It is structured based on the 2013-2018 Rwanda TB national strategic plan (2013-2018 ... more

Download (362)

View PDF (617)

Global plan for insecticide resistance management in malaria vectors

World Health Organization (WHO) (2012) C_WHO

The plan contains the latest available evidence on the extent of insecticide resistance around the world, and puts forward a strategy for global and country levels, identifying clear roles and timelines for all stakeholders. The GPIRM also summarizes information about innovative new products being d... more

Guidelines for the Clinical Management of HIV Infection in Myanmar, 5th ed. recommended

Management of physical health conditions in adults with severe mental disorders recommended

Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline recommended

Guidelines on hepatitis B and C testing recommended

Guidelines for the Clinical Management of HIV Infection in Myanmar, 5th ed.
recommended

Management of physical health conditions in adults with severe mental disorders
recommended

Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline
recommended

Guidelines on hepatitis B and C testing
recommended